Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

Carl L. Gordon

AddedMar 31, 2024

UpdatedMay 31, 2026

Carl L. Gordon

Carl L. Gordon

Board Member, Terns Pharmaceuticals

Carl L. Gordon's Career

Terns Pharmaceuticals

Terns Pharmaceuticals

Foster City, CA, US

Board Member· Board

Keros Therapeutics

Keros Therapeutics

Lexington, MA, US

Board Member· Board

SpringWorks Therapeutics

SpringWorks Therapeutics

Stamford, CT, US

Board Member· Board

Alector

San Francisco, CA, US

Board Member· Board

Igenica

Burlingame, CA, US

Board Member· Board

Adimab

Lebanon, NH, US

Board Member· Board

MBX Biosciences

MBX Biosciences

Carmel, IN, US

Board Member· Board

Scribe Therapeutics

Scribe Therapeutics

Alameda, CA, US

Board Member· Board

Odyssey Therapeutics

Odyssey Therapeutics

Cambridge, MA, US

Board Member· Board

Singulex

Alameda, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Carl L. Gordon's Career

Terns Pharmaceuticals

Terns Pharmaceuticals

Public$348.3M302016Foster City, CA, US

Board Member· Board

Leadership at Terns Pharmaceuticals

Jill Thompson QuigleyBoard Member

David FellowsBoard Member

Radhika TripuraneniBoard Member

Weidong ZhongBoard Member

Senthil SundaramCEO

Jeff KindlerBoard Member

Keros Therapeutics

Keros Therapeutics

Public$230M1052015Lexington, MA, US

Board Member· Board

Leadership at Keros Therapeutics

Jasbir SeehraCo-Founder

Mary Ann GrayBoard Member

Paul YuBoard Member

Ran NussbaumBoard Member

Tomer KarivBoard Member

Similar to Keros Therapeutics

KereosSt. Louis, MO, USImaging Agents, Therapeuticsest. 1999KereosSt. Louis, MO, US · est. 1999

Kereos: A biotech firm innovating molecular imaging agents for cancer and heart disease treatment.

Series B · $27.2M9

Kymera TherapeuticsWatertown, MA, USDrugsest. 2017Kymera TherapeuticsWatertown, MA, US · est. 2017

Kymera Therapeutics, a global biopharmaceutical firm, innovates drugs for untreatable acute and chronic diseases.

Public · $879M167

Kestrel TherapeuticsWayland, MA, USCancer Treatmentest. 2020Kestrel TherapeuticsWayland, MA, US · est. 2020

Kestrel Therapeutics: Pioneering RAS cancer treatment solutions through medical research.

Series A · $40M6

Kezar Life SciencesSouth San Francisco, CA, USMedicines, Therapeuticsest. 2015Kezar Life SciencesSouth San Francisco, CA, US · est. 2015

Kezar Life Sciences, a biotech firm, develops molecular therapeutics for autoimmune disorders in California.

Public · $123M84

SpringWorks Therapeutics

SpringWorks Therapeutics

Public$1B2272017Stamford, CT, US

Board Member· Board

Leadership at SpringWorks Therapeutics

Carlos AlbanBoard Member

Alan FuhrmanBoard Member

Dan LynchBoard Member

Julie HambletonBoard Member

Saqib IslamBoard Member

Lara S. SullivanFounder

Alector

Public$269.5M2732013San Francisco, CA, US

Board Member· Board

Leadership at Alector

Arnon RosenthalBoard Member

Richard SchellerBoard Member

Dave WehnerBoard Member

Louis J. Lavigne Jr.Board Member

Igenica

Pre-Seed$80.6M112008Burlingame, CA, US

Board Member· Board

Leadership at Igenica

Mark A. GoldsmithBoard Member

Robert SchreiberBoard Member

David GoeddelBoard Member

John DiekmanBoard Member

Adimab

Public$45.5M1492007Lebanon, NH, US

Board Member· Board

Leadership at Adimab

Fran HellerBoard Member

Tillman GerngrossBoard Member

K. Dane WittrupBoard Member

Terry McguireBoard Member

Philip ChaseBoard Member

Bill MarisBoard Member

MBX Biosciences

MBX Biosciences

Series B$174.9M332019Carmel, IN, US

Board Member· Board

Leadership at MBX Biosciences

Patrick HeronBoard Member

Ed MathersBoard Member

Timothy KnickerbockerFounder

Kent HawrylukCEO

Similar to MBX Biosciences

Merganser BiotechNewtown Square, PA, USMedicineest. 2011Merganser BiotechNewtown Square, PA, US · est. 2011

Merganser Biotech Inc., a medicine development company, innovates therapeutic treatments for human diseases.

Series B · $28M30

Petri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Xeno BiosciencesCambridge, MA, USBiopharmaceuticals, Therapeuticsest. 2015Xeno BiosciencesCambridge, MA, US · est. 2015

Xeno Biosciences, a biopharmaceutical pioneer, develops novel therapeutics for metabolic diseases.

Empire BiotechnologiesSan Francisco, CA, USTherapeuticsest. 2013Empire BiotechnologiesSan Francisco, CA, US · est. 2013

Empire Biotechnologies: Innovating therapies for unmet medical needs, focusing on malabsorption diseases.

Pre-Seed · $1.1M1

Scribe Therapeutics

Scribe Therapeutics

Late Stage Private$120M1212017Alameda, CA, US

Board Member· Board

Leadership at Scribe Therapeutics

Benjamin L OakesCo-Founder

David SavageCo-Founder

Jennifer DoudnaCo-Founder

Brett T StaahlCo-Founder

Odyssey Therapeutics

Odyssey Therapeutics

Series C$487M1752021Cambridge, MA, US

Board Member· Board

Leadership at Odyssey Therapeutics

Gary GlickBoard Member

Jill CarrollBoard Member

Jeffrey LeidenBoard Member

Valerie OdegardBoard Member

David L. PomplianoCo-Founder

Charles Baum, MD, PhDBoard Member

Similar to Odyssey Therapeutics

Odyssey TheraSan Ramon, CA, USCancer Therapiesest. 2000Odyssey TheraSan Ramon, CA, US · est. 2000

Odyssey Thera, Inc.: A US-based biopharmaceutical company specializing in cancer therapies.

Public · $6.3M30

Nested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50

Synnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18

Scorpion TherapeuticsBoston, MA, USCancer Treatmentest. 2020Scorpion TherapeuticsBoston, MA, US · est. 2020

Scorpion Therapeutics, a Boston-based medical organization, innovates in precision oncology for enhanced cancer treatment.

Series B · $270M130

Singulex

Acquired$227.3M01997Alameda, CA, US

Board Member· Board

Leadership at Singulex

Heiner DreismannBoard Member

Richard PoppBoard Member

Andre MarionBoard Member

Guido BaechlerCEO

Steve RoseBoard Member

Similar to Singulex

IncellDxMenlo Park, CA, USMedical Instrumentsest. 2009IncellDxMenlo Park, CA, US · est. 2009

IncellDx, a California-based medical firm, develops and distributes diagnostic instruments for life-threatening diseases globally.

Series A · $9M26

Accelevir DiagnosticsBaltimore, MD, USBiotech Assaysest. 2015Accelevir DiagnosticsBaltimore, MD, US · est. 2015

Accelevir Diagnostics: Innovating biotech assays for ultra-rare analytes in infectious diseases.

Pre-Seed · $1.4M7

Singular GenomicsSan Diego, CA, USGenomic Technologiesest. 2016Singular GenomicsSan Diego, CA, US · est. 2016

Singular Genomics: A dynamic, fast-paced biotech company in California, innovating in genomic technologies.

Public · $176M134

Amplified SciencesWest Lafayette, IN, USDiagnostics, Disease Detectionest. 2016Amplified SciencesWest Lafayette, IN, US · est. 2016

Amplified Sciences: A life science diagnostics firm specializing in early disease detection.

Angel · $4.7M13

Carl L. Gordon's Similar Executives & Operators

Lau Eng BoonBoard Member · Bukalapak

Jay Geoffrey WacherBoard Member · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

WILL WEI CHENGBoard Member · DiDi

Dhirubhai H. AmbaniBoard Member · Reliance Retail

Mason YeoBoard Member · Kakao

JaeHong ChoiBoard Member · Kakao

Sean JohBoard Member · Kakao

People Similar to Carl L. Gordon

Rishi GuptaBoard Member · Aer Therapeutics

Q Khuong ChauBoard Member · NextCure

Michael B ShefferyCo-Founder · OrbiMed Advisors

Sam IsalyFounder · Exome Asset Management

Lee SolomonBoard Member · ADT